ATE332363T1 - Rekombinanter adenovirus welcher eine chimäre penton-base aufweist - Google Patents
Rekombinanter adenovirus welcher eine chimäre penton-base aufweistInfo
- Publication number
- ATE332363T1 ATE332363T1 AT95928312T AT95928312T ATE332363T1 AT E332363 T1 ATE332363 T1 AT E332363T1 AT 95928312 T AT95928312 T AT 95928312T AT 95928312 T AT95928312 T AT 95928312T AT E332363 T1 ATE332363 T1 AT E332363T1
- Authority
- AT
- Austria
- Prior art keywords
- recombinant adenovirus
- penton base
- chimeric penton
- chimeric
- adenovirus
- Prior art date
Links
- 241000701161 unidentified adenovirus Species 0.000 title abstract 4
- 101710173835 Penton protein Proteins 0.000 abstract 2
- 238000001415 gene therapy Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70546—Integrin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10345—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14041—Use of virus, viral particle or viral elements as a vector
- C12N2710/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
- C12N2810/405—Vectors comprising RGD peptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
- C12N2810/6018—Adenoviridae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
- C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
- C12N2810/855—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from receptors; from cell surface antigens; from cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
- C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
- C12N2810/855—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from receptors; from cell surface antigens; from cell surface determinants
- C12N2810/856—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from receptors; from cell surface antigens; from cell surface determinants from integrins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
- C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
- C12N2810/859—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/303,162 US5559099A (en) | 1994-09-08 | 1994-09-08 | Penton base protein and methods of using same |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE332363T1 true ATE332363T1 (de) | 2006-07-15 |
Family
ID=23170789
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT95928312T ATE332363T1 (de) | 1994-09-08 | 1995-08-07 | Rekombinanter adenovirus welcher eine chimäre penton-base aufweist |
Country Status (8)
Country | Link |
---|---|
US (3) | US5559099A (de) |
EP (2) | EP0778889B1 (de) |
JP (1) | JPH10505242A (de) |
AT (1) | ATE332363T1 (de) |
AU (1) | AU684220B2 (de) |
CA (1) | CA2198861A1 (de) |
DE (1) | DE69535103D1 (de) |
WO (1) | WO1996007734A2 (de) |
Families Citing this family (179)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9223084D0 (en) * | 1992-11-04 | 1992-12-16 | Imp Cancer Res Tech | Compounds to target cells |
US5543328A (en) * | 1993-08-13 | 1996-08-06 | Genetic Therapy, Inc. | Adenoviruses having modified fiber proteins |
GB9412844D0 (en) * | 1994-06-27 | 1994-08-17 | Medical Res Council | Improvements in or relating to therapeutic methods |
US5559099A (en) * | 1994-09-08 | 1996-09-24 | Genvec, Inc. | Penton base protein and methods of using same |
US5962311A (en) * | 1994-09-08 | 1999-10-05 | Genvec, Inc. | Short-shafted adenoviral fiber and its use |
US6465253B1 (en) * | 1994-09-08 | 2002-10-15 | Genvec, Inc. | Vectors and methods for gene transfer to cells |
US5846782A (en) | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
US5965541A (en) * | 1995-11-28 | 1999-10-12 | Genvec, Inc. | Vectors and methods for gene transfer to cells |
US6127525A (en) * | 1995-02-21 | 2000-10-03 | Cornell Research Foundation, Inc. | Chimeric adenoviral coat protein and methods of using same |
US5770442A (en) | 1995-02-21 | 1998-06-23 | Cornell Research Foundation, Inc. | Chimeric adenoviral fiber protein and methods of using same |
US6783980B2 (en) * | 1995-06-15 | 2004-08-31 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
ES2333425T5 (es) * | 1995-06-15 | 2012-08-28 | Crucell Holland B.V. | Sistemas de empaquetado para adenovirus recombinante humano destinados a terapia génica |
EP0840797B1 (de) * | 1995-07-25 | 2014-09-03 | Crucell Holland B.V. | Verfahren und mittel zur gezielten freisetzung von genen |
CZ162398A3 (cs) * | 1995-11-28 | 1998-10-14 | Gen Vec, Inc. | Vektory a způsoby pro genový přenos do buněk |
US6136311A (en) | 1996-05-06 | 2000-10-24 | Cornell Research Foundation, Inc. | Treatment and diagnosis of cancer |
FR2751343B1 (fr) * | 1996-07-16 | 1998-12-18 | Transgene Sa | Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament |
WO1998013499A2 (en) * | 1996-09-25 | 1998-04-02 | Novartis Ag | Packaging cell lines for use in facilitating the development of high-capacity adenoviral vectors |
US7232899B2 (en) * | 1996-09-25 | 2007-06-19 | The Scripps Research Institute | Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use |
FR2756297B1 (fr) * | 1996-11-22 | 1999-01-08 | Centre Nat Rech Scient | Procede de production de virus recombinants |
AU6691098A (en) | 1997-03-07 | 1998-09-22 | Wistar Institute Of Anatomy & Biology, The | Method and compositions for healing tissue defects and inducing hypervascularityin mammalian tissue |
US6218597B1 (en) | 1997-04-03 | 2001-04-17 | University Technology Corporation | Transgenic model and treatment for heart disease |
NZ501140A (en) * | 1997-05-28 | 2001-07-27 | Genvec Inc | Adenoviral fiber trimer with reduced affinity for native cell surface receptors |
IL132596A0 (en) * | 1997-06-04 | 2001-03-19 | Oxford Biomedica Ltd | Vector |
US7635687B2 (en) * | 1997-06-04 | 2009-12-22 | Oxford Biomedica (Uk) Limited | Vector system |
US7276488B2 (en) * | 1997-06-04 | 2007-10-02 | Oxford Biomedica (Uk) Limited | Vector system |
WO1999041359A1 (en) * | 1998-02-17 | 1999-08-19 | The Uab Research Foundation | Modified adenovirus containing a fiber replacement protein |
AU3358999A (en) * | 1998-03-20 | 1999-10-11 | Genzyme Corporation | Chimeric adenoviral vectors for targeted gene delivery |
WO1999055365A1 (en) | 1998-04-30 | 1999-11-04 | Cornell Research Foundation, Inc. | Adenoviral vectors with tandem fiber proteins |
AU4089899A (en) | 1998-05-20 | 1999-12-06 | University Of Tennessee Research Corporation, The | Stable envelope proteins for retroviral, viral and liposome vectors and use in gene and drug therapy |
US20040043489A1 (en) * | 1998-07-08 | 2004-03-04 | Menzo Havenga | Gene delivery vectors provided with a tissue tropism for dendritic cells and methods of use |
US20030017138A1 (en) * | 1998-07-08 | 2003-01-23 | Menzo Havenga | Chimeric adenoviruses |
US6455314B1 (en) | 1998-09-11 | 2002-09-24 | Genvec, Inc. | Alternatively targeted adenovirus |
US6929946B1 (en) | 1998-11-20 | 2005-08-16 | Crucell Holland B.V. | Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells |
US6649396B1 (en) * | 1999-02-05 | 2003-11-18 | Uab Research Foundation | Fiber receptor-independent system for the propagation of adenoviral vectors |
US20050232900A1 (en) * | 1999-05-18 | 2005-10-20 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
US6492169B1 (en) * | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
US6913922B1 (en) * | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
US7261881B1 (en) | 1999-05-20 | 2007-08-28 | Yale University | Modulation of angiogenesis and wound healing |
US6740511B1 (en) | 1999-08-27 | 2004-05-25 | Transgene S.A. | Modified adenoviral fibre and uses thereof |
ES2183752T3 (es) * | 1999-09-17 | 2005-07-16 | Tgt Laboratories, S.A. De C.V. | Vectores adenovirales recombinantes y su utilizacion en el tratamiento de la cirrosis de higado. |
AU1290001A (en) * | 1999-11-18 | 2001-05-30 | Oxford Biomedica (Uk) Limited | Antibodies |
EP1157999A1 (de) * | 2000-05-24 | 2001-11-28 | Introgene B.V. | Verfahren und Mitteln zur Verbesserung der Haut-Transplantation mittels Genabgabe-Vehikel mit Tropismus für primären Fibroblasten, sowie andere Verwendungsmöglichkeiten für diesen |
WO2001092547A2 (en) * | 2000-05-31 | 2001-12-06 | University Of Saskatchewan | Modified bovine adenovirus having altered tropism |
AU2001265154A1 (en) * | 2000-05-31 | 2001-12-11 | Genvec, Inc. | Method and composition for targeting an adenoviral vector |
US7355019B2 (en) * | 2000-06-06 | 2008-04-08 | Sibtech, Inc. | Cysteine-containing peptide tag for site-specific conjugation of proteins |
US20020164333A1 (en) * | 2000-07-10 | 2002-11-07 | The Scripps Research Institute | Bifunctional molecules and vectors complexed therewith for targeted gene delivery |
AU2002223556A1 (en) * | 2000-09-20 | 2002-04-02 | Crucell Holland B.V. | Transduction of dendritic cells using adenoviral vectors |
US7235233B2 (en) * | 2000-09-26 | 2007-06-26 | Crucell Holland B.V. | Serotype 5 adenoviral vectors with chimeric fibers for gene delivery in skeletal muscle cells or myoblasts |
US6573092B1 (en) | 2000-10-10 | 2003-06-03 | Genvec, Inc. | Method of preparing a eukaryotic viral vector |
US20030202963A1 (en) * | 2000-10-12 | 2003-10-30 | Cornell Research Foundation, Inc. | Method of treating cancer |
MXPA00011713A (es) * | 2000-11-28 | 2002-05-31 | Tgt Lab S A De C V | Vectores recombinantes virales y no virales conteniendo el gen humano del activador de plasminogeno derivado de urocinasa y su utilidad en el tratamiento de diversos tipos de fibrosis hepatica, renal, pulmonar, pancreatica, cardiaca y cicatrices hipe |
US20020151069A1 (en) * | 2001-04-17 | 2002-10-17 | Nikolay Korokhov | Mosaic adenoviral vectors |
US20060275262A1 (en) * | 2001-07-26 | 2006-12-07 | Mathis James M | Conditionally replicating viruses and methods for cancer virotherapy |
GB0119852D0 (en) * | 2001-08-15 | 2001-10-10 | Univ York | Baculovirus |
US7217570B2 (en) * | 2001-08-23 | 2007-05-15 | The Wistar Institute Of Anatomy And Biology | Organotypic intestinal culture and methods of use thereof |
US7247297B2 (en) * | 2001-09-14 | 2007-07-24 | The University Of Chicago | Use of DF3/MUC1 regulated expression in gene therapy |
US20040031067A1 (en) * | 2001-10-11 | 2004-02-12 | Meenhard Herlyn | Regulation of human skin healing |
GB0126378D0 (en) * | 2001-11-02 | 2002-01-02 | Oxford Biomedica Ltd | Antigen |
JP4488290B2 (ja) * | 2002-01-24 | 2010-06-23 | ザ・スクリップス・リサーチ・インスティテュート | 効率的ターゲティングのためのファイバーシャフト変異 |
EP1497438B1 (de) * | 2002-04-25 | 2009-10-28 | Crucell Holland B.V. | Mittel und verfahren zur herstellung von adenovirusvektoren |
US7858367B2 (en) * | 2002-04-30 | 2010-12-28 | Duke University | Viral vectors and methods for producing and using the same |
AU2003268145A1 (en) * | 2002-08-22 | 2004-03-11 | Merck And Co., Inc. | Methods for propagating adenovirus and virus produced thereby |
US9701754B1 (en) | 2002-10-23 | 2017-07-11 | City Of Hope | Covalent disulfide-linked diabodies and uses thereof |
US20040248262A1 (en) | 2003-01-22 | 2004-12-09 | Koeberl Dwight D. | Constructs for expressing lysomal polypeptides |
US20040166091A1 (en) * | 2003-02-24 | 2004-08-26 | Genvec, Inc. | Materials and methods for treating disorders of the ear |
US20070212675A1 (en) * | 2003-04-15 | 2007-09-13 | Novartis Ag | Flap Endonuclease (Fen1) Regulatory Sequences And Uses Thereof |
WO2004092397A2 (en) * | 2003-04-15 | 2004-10-28 | Novartis Ag | Tmprss2 regulatory sequences and uses thereof |
CA2527721C (en) * | 2003-06-10 | 2016-05-10 | University Of Saskatchewan | Chimeric adenovirus capsid proteins |
US7291498B2 (en) * | 2003-06-20 | 2007-11-06 | The Trustees Of The University Of Pennsylvania | Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses |
ES2478625T3 (es) * | 2003-06-20 | 2014-07-22 | The Trustees Of The University Of Pennsylvania | Método de generación de adenovirus quiméricos y usos de tales adenovirus quiméricos |
ES2391975T3 (es) * | 2003-07-25 | 2012-12-03 | Genvec, Inc. | Vacunas a base de vector adenovírico |
US7519698B2 (en) * | 2003-09-26 | 2009-04-14 | Ricoh Co., Ltd. | Method and system for extracting information from networked devices in a multi-protocol remote monitoring system |
WO2005051432A1 (en) * | 2003-11-14 | 2005-06-09 | Genvec, Inc. | Therapeutic regimen for treating cancer |
EP1718738A2 (de) * | 2004-02-23 | 2006-11-08 | Crucell Holland B.V. | Verfahren zur reinigung von viren |
US7473418B2 (en) * | 2004-03-25 | 2009-01-06 | Cell Genesys, Inc. | Pan cancer oncolytic vectors and methods of use thereof |
US20070207166A1 (en) | 2004-04-12 | 2007-09-06 | Genvec, Inc. | Method of Using Adenoviral Vectors to Induce an Immune Response |
US20060062764A1 (en) * | 2004-08-25 | 2006-03-23 | Seshidar-Reddy Police | Fiber-modified adenoviral vectors for enhanced transduction of tumor cells |
WO2006039045A2 (en) * | 2004-09-01 | 2006-04-13 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adenoviral vectors able to transduce apcs, potential use in immune response generation |
US20070275874A1 (en) * | 2004-09-03 | 2007-11-29 | Yale University | Use of Leptin in Wound Healing |
US20060205080A1 (en) * | 2005-03-01 | 2006-09-14 | David Frey | Formulations for therapeutic viruses having enhanced storage stability |
CN101155915B (zh) * | 2005-04-11 | 2013-12-04 | 克鲁塞尔荷兰公司 | 利用超滤进行病毒纯化 |
US20060234347A1 (en) * | 2005-04-13 | 2006-10-19 | Harding Thomas C | Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors |
BRPI0615400A2 (pt) * | 2005-08-31 | 2011-05-17 | Genvec Inc | vacinas para malária baseadas em vetor adenoviral |
US9651543B2 (en) | 2005-08-31 | 2017-05-16 | The United States Of America As Represented By The Secretary Of The Navy | Malaria antigen screening method |
US8450055B2 (en) * | 2005-08-31 | 2013-05-28 | The United States Of America As Represented By The Secretary Of The Navy | Malaria antigen screening method |
BRPI0618441B8 (pt) * | 2005-11-10 | 2021-07-27 | Genvec Inc | vetor adenoviral |
ES2363891T3 (es) | 2006-03-20 | 2011-08-18 | The Regents Of The University Of California | Anticuerpos contra el antígeno de células troncales de la próstata (psca) modificados genéticamente para el direccionamiento al cáncer. |
US9868961B2 (en) | 2006-03-30 | 2018-01-16 | The Regents Of The University Of California | Methods and compositions for localized secretion of anti-CTLA-4 antibodies |
US7919079B2 (en) | 2006-03-31 | 2011-04-05 | Biosante Pharmaceuticals, Inc. | Cancer immunotherapy compositions and methods of use |
EP2114445A2 (de) * | 2007-01-09 | 2009-11-11 | Genvec, Inc. | Auf adenoviralen vektoren basierende malaria-impfstoffe |
WO2009009441A2 (en) | 2007-07-06 | 2009-01-15 | Cedars-Sinai Medical Center | Self-assembling complex for targeting chemical agents to cells |
WO2009032949A2 (en) | 2007-09-04 | 2009-03-12 | The Regents Of The University Of California | High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection |
WO2009046294A2 (en) * | 2007-10-03 | 2009-04-09 | Cornell University | Treatment of proliferative disorders using antibodies to psma |
US20090202492A1 (en) * | 2008-01-25 | 2009-08-13 | University Of South Florida | Adenovirus vaccine utilizing ikk as adjuvant |
JP5552065B2 (ja) * | 2008-03-14 | 2014-07-16 | ダウ グローバル テクノロジーズ エルエルシー | ポリマー物品の改良造形プロセス |
US20100069616A1 (en) * | 2008-08-06 | 2010-03-18 | The Regents Of The University Of California | Engineered antibody-nanoparticle conjugates |
PL2350268T3 (pl) * | 2008-11-03 | 2015-05-29 | Crucell Holland Bv | Sposób wytwarzania wektorów adenowirusowych |
WO2010085665A2 (en) | 2009-01-23 | 2010-07-29 | Cedars-Sinai Medical Center | Targeted delivery system |
US10517969B2 (en) * | 2009-02-17 | 2019-12-31 | Cornell University | Methods and kits for diagnosis of cancer and prediction of therapeutic value |
US9605844B2 (en) * | 2009-09-01 | 2017-03-28 | Cree, Inc. | Lighting device with heat dissipation elements |
PL2488635T3 (pl) | 2009-10-15 | 2014-04-30 | Crucell Holland Bv | Proces do oczyszczania adenowirusa z hodowli o dużej gęstości komórek |
WO2011045378A1 (en) | 2009-10-15 | 2011-04-21 | Crucell Holland B.V. | Method for the purification of adenovirus particles |
WO2011047316A1 (en) | 2009-10-16 | 2011-04-21 | The United States Of America, As Represented By The Secretary Department Of Health And Human Services | Nucleic acid sequences encoding expandable hiv mosaic proteins |
US9133248B2 (en) | 2009-11-09 | 2015-09-15 | Genvec, Inc. | Methods of propagating monkey adenoviral vectors |
WO2011057254A2 (en) | 2009-11-09 | 2011-05-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Simian adenoviral vector-based vaccines |
US8772459B2 (en) | 2009-12-02 | 2014-07-08 | Imaginab, Inc. | J591 minibodies and Cys-diabodies for targeting human prostate specific membrane antigen (PSMA) and methods for their use |
EP2536829B1 (de) | 2010-02-15 | 2016-04-06 | Crucell Holland B.V. | Verfahren zur Herstellung von adenoviralen Ad26-Vektoren |
WO2011116189A1 (en) | 2010-03-17 | 2011-09-22 | Cornell University | Disrupted adenovirus-based vaccine against drugs of abuse |
BR112012024166A2 (pt) | 2010-03-23 | 2022-09-27 | Intrexon Corp | Vetores condicionalmente expressando proteínas terapêuticas, células hospedeiras compreendendo os vetores, e usos dos mesmos |
WO2012021730A2 (en) | 2010-08-11 | 2012-02-16 | Genvec, Inc. | Respiratory syncytial virus (rsv) vaccine |
CN103118702A (zh) | 2010-09-20 | 2013-05-22 | 克鲁塞尔荷兰公司 | 活动性结核病的治疗性接种 |
AU2011310838B2 (en) | 2010-09-27 | 2015-11-05 | Crucell Holland B.V. | Heterologous prime boost vaccination regimen against malaria |
US9512429B2 (en) | 2010-12-06 | 2016-12-06 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Pharmaceutical composition comprising Nanog shRNA, and method of using Nanog shRNA to treat cancer |
WO2012083297A2 (en) | 2010-12-17 | 2012-06-21 | Genvec, Inc. | Adenoviral vectors with modified hexon regions |
EP2654786B1 (de) | 2010-12-20 | 2019-02-20 | GenVec, Inc. | Auf adenovirusvektor basierender impfstoff gegen denguefieber |
CN103534355A (zh) | 2011-03-04 | 2014-01-22 | 英特瑞克斯顿股份有限公司 | 条件性表达蛋白质的载体 |
WO2013074501A1 (en) | 2011-11-14 | 2013-05-23 | Crucell Holland B.V. | Heterologous prime-boost immunization using measles virus-based vaccines |
EA034284B1 (ru) | 2012-03-12 | 2020-01-24 | Янссен Вэксинс Энд Превеншн Б.В. | Частицы рекомбинантного трансгенсодержащего аденовируса с 5'-концевыми нуклеотидами ctatctat |
US8932607B2 (en) | 2012-03-12 | 2015-01-13 | Crucell Holland B.V. | Batches of recombinant adenovirus with altered terminal ends |
EP2827894B1 (de) | 2012-03-22 | 2017-05-17 | Janssen Vaccines & Prevention B.V. | Impfstoff gegen rsv |
US9119813B2 (en) | 2012-03-22 | 2015-09-01 | Crucell Holland B.V. | Vaccine against RSV |
WO2013181128A1 (en) | 2012-05-29 | 2013-12-05 | Genvec, Inc. | Modified serotype 28 adenoviral vectors |
JP6618360B2 (ja) | 2012-08-03 | 2019-12-11 | セダーズ−シナイ メディカル センター | 薬物送達タンパク質の輸送向上変異体の単離 |
EP2971008B1 (de) | 2013-03-14 | 2018-07-25 | Salk Institute for Biological Studies | Onkolytische adenoviruszusammensetzungen |
CA2908253C (en) | 2013-04-04 | 2024-01-09 | Trustees Of Dartmouth College | Compositions and methods for in vivo excision of hiv-1 proviral dna |
PT2988780T (pt) | 2013-04-25 | 2019-03-25 | Janssen Vaccines & Prevention Bv | Polipeptídeos f de pré-fusão do rsv solúveis estabilizados |
CA2910030A1 (en) | 2013-05-08 | 2014-11-13 | Lali K. Medina-Kauwe | Targeting corroles for tumor toxicity and mri |
WO2014202570A1 (en) | 2013-06-17 | 2014-12-24 | Crucell Holland B.V. | Stabilized soluble pre-fusion rsv f polypeptides |
DK3046536T3 (en) | 2013-09-19 | 2019-03-11 | Janssen Vaccines & Prevention Bv | IMPROVED ADENOVIRUS FORMULATIONS |
US10183078B2 (en) | 2014-01-17 | 2019-01-22 | Cedars-Sinai Medical Center | Receptor targeting constructs and uses thereof |
CA2943297A1 (en) | 2014-04-04 | 2015-10-08 | Cedars-Sinai Medical Center | Targeting trastuzumab-resistant her2+ breast cancer with a her3-targeting nanoparticle |
TWI710635B (zh) | 2014-10-09 | 2020-11-21 | 美商珍維克公司 | 編碼人類無調同源物-1(hath1)之腺病毒載體 |
NZ730802A (en) | 2014-11-04 | 2021-12-24 | Janssen Vaccines & Prevention Bv | Therapeutic hpv16 vaccines |
JP2018504141A (ja) | 2015-01-20 | 2018-02-15 | アドキュア バイオテクノロジーズ、 エルエルシー | 非標的化アデノウイルス変異体および関連する方法 |
WO2016146844A1 (en) | 2015-03-18 | 2016-09-22 | Janssen Vaccines & Prevention B.V. | Assays for recombinant expression systems |
SI3283634T1 (sl) | 2015-04-14 | 2019-08-30 | Janssen Vaccines & Prevention B.V. | Rekombinantni adenovirus, ki izraža dva transgena z dvosmernim promotorjem |
BR112017027448A2 (pt) | 2015-07-07 | 2018-09-04 | Janssen Vaccines & Prevention Bv | vacina contra rsv |
CA2991540A1 (en) | 2015-07-07 | 2017-01-12 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion respiratory syncytial sirus polypeptides |
US11254744B2 (en) | 2015-08-07 | 2022-02-22 | Imaginab, Inc. | Antigen binding constructs to target molecules |
JP6470872B2 (ja) | 2015-08-20 | 2019-02-13 | ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. | 治療用hpv18ワクチン |
US20180280519A1 (en) | 2015-10-06 | 2018-10-04 | Janssen Vaccines & Prevention B.V. | Methods for preventing plastic-induced degradation of biologicals |
WO2017070113A1 (en) | 2015-10-19 | 2017-04-27 | The United States of America, as represented by the Secretary, Department of Health and Human Sevices | Pharmaceutical composition comprising nanog shrna, and method of using nanog shrna to treat cancer |
CA3013637A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
JP7015551B2 (ja) | 2016-02-23 | 2022-02-15 | ソーク インスティテュート フォー バイオロジカル スタディーズ | ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現 |
US11155583B2 (en) | 2016-04-05 | 2021-10-26 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion RSV F proteins |
MA43762A (fr) | 2016-04-05 | 2021-04-21 | Janssen Vaccines & Prevention Bv | Vaccin contre le rsv |
BR112018072372A2 (pt) | 2016-05-02 | 2019-02-19 | Janssen Vaccines & Prevention B.V. | combinações de vacina terapêutica contra o hpv |
ES2829272T3 (es) | 2016-05-12 | 2021-05-31 | Janssen Vaccines & Prevention Bv | Promotor bidireccional potente y equilibrado |
CA3025441A1 (en) | 2016-05-30 | 2017-12-07 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion rsv f proteins |
MX2018015540A (es) | 2016-06-20 | 2019-04-11 | Janssen Vaccines & Prevention Bv | Promotor bidireccional potente y equilibrado. |
EP3484506A1 (de) | 2016-07-14 | 2019-05-22 | Janssen Vaccines & Prevention B.V. | Hpv-impfstoffe |
CA3038968A1 (en) | 2016-09-30 | 2018-04-05 | Genvec, Inc. | Adenovectors for delivery of therapeutic genetic material into t cells |
CN110062630A (zh) | 2016-12-12 | 2019-07-26 | 萨克生物研究学院 | 肿瘤靶向合成腺病毒及其用途 |
US11266745B2 (en) | 2017-02-08 | 2022-03-08 | Imaginab, Inc. | Extension sequences for diabodies |
AU2018217935B2 (en) | 2017-02-09 | 2020-04-30 | Janssen Vaccines & Prevention B.V. | Potent and short promoter for expression of heterologous genes |
EP3624844A1 (de) | 2017-05-17 | 2020-03-25 | Janssen Vaccines & Prevention B.V. | Verfahren und zusammensetzungen zur induzierung schützender immunität gegen rsv-infektionen |
MX2020002876A (es) | 2017-09-15 | 2020-07-22 | Janssen Vaccines & Prevention Bv | Metodo para la induccion segura de inmunidad contra el vsr. |
KR20200077559A (ko) | 2017-10-31 | 2020-06-30 | 얀센 백신스 앤드 프리벤션 비.브이. | 아데노바이러스 및 이의 용도 |
SG11202003398SA (en) | 2017-10-31 | 2020-05-28 | Janssen Vaccines & Prevention Bv | Adenovirus vectors and uses thereof |
SG11202003290RA (en) | 2017-10-31 | 2020-05-28 | Janssen Vaccines & Prevention Bv | Adenovirus and uses thereof |
JP7438943B2 (ja) | 2017-10-31 | 2024-02-27 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | アデノウイルス及びその用途 |
SG11202006399VA (en) | 2018-01-23 | 2020-08-28 | Janssen Vaccines & Prevention Bv | Influenza virus vaccines and uses thereof |
TW202043256A (zh) | 2019-01-10 | 2020-12-01 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
EP3927833A4 (de) | 2019-02-21 | 2022-11-30 | Unleash Immuno Oncolytics, Inc. | Onkolytischer adenoviraler vektor und verfahren zur verwendung |
AU2020263900A1 (en) | 2019-04-25 | 2021-10-14 | Janssen Vaccines & Prevention B.V. | Recombinant influenza antigens |
MX2021013947A (es) | 2019-05-15 | 2021-12-14 | Janssen Vaccines & Prevention Bv | Tratamiento profilactico de la infeccion por virus sincitial respiratorio con una vacuna basada en adenovirus. |
US20220273787A1 (en) | 2019-05-15 | 2022-09-01 | Janssen Vaccines & Prevention B.V. | Co-administration of seasonal influenza vaccine and an adenovirus based respiratory syncytial virus vaccine |
WO2021043869A1 (en) | 2019-09-05 | 2021-03-11 | Janssen Vaccines & Prevention B.V. | Influenza virus vaccines and uses thereof |
MX2022004028A (es) | 2019-10-03 | 2022-05-02 | Janssen Vaccines & Prevention Bv | Vectores de adenovirus y usos de los mismos. |
WO2021072129A2 (en) | 2019-10-08 | 2021-04-15 | Trustees Of Boston College | Proteins containing multiple, different unnatural amino acids and methods of making and using such proteins |
PE20221182A1 (es) | 2019-11-18 | 2022-08-05 | Janssen Biotech Inc | Vacunas basadas en calr y jak2 mutantes y sus usos |
TW202144388A (zh) | 2020-02-14 | 2021-12-01 | 美商健生生物科技公司 | 在卵巢癌中表現之新抗原及其用途 |
TW202144389A (zh) | 2020-02-14 | 2021-12-01 | 美商健生生物科技公司 | 在多發性骨髓瘤中表現之新抗原及其用途 |
AU2021357520A1 (en) | 2020-03-05 | 2022-09-29 | Neotx Therapeutics Ltd. | Methods and compositions for treating cancer with immune cells |
EP4135757A1 (de) | 2020-04-13 | 2023-02-22 | Janssen Biotech, Inc. | Psma- und steap1-impfstoffe und ihre verwendungen |
US20230029453A1 (en) | 2020-07-06 | 2023-02-02 | Janssen Biotech, Inc. | Prostate Neoantigens And Their Uses |
WO2022009051A1 (en) | 2020-07-06 | 2022-01-13 | Janssen Biotech, Inc. | A method for determining responsiveness to prostate cancer treatment |
EP4175721A1 (de) | 2020-07-06 | 2023-05-10 | Janssen Biotech, Inc. | Prostata-neoantigene und ihre verwendungen |
EP4338727A1 (de) | 2022-09-14 | 2024-03-20 | Roquette Freres | Adenovirus-formulierungen |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4593002A (en) * | 1982-01-11 | 1986-06-03 | Salk Institute Biotechnology/Industrial Associates, Inc. | Viruses with recombinant surface proteins |
US4487829A (en) * | 1982-03-23 | 1984-12-11 | Massachusetts Institute Of Technology | Production and use of monoclonal antibodies against adenoviruses |
US4792525A (en) * | 1982-08-04 | 1988-12-20 | La Jolla Cancer Research Foundation | Tetrapeptide |
US4578079A (en) * | 1982-08-04 | 1986-03-25 | La Jolla Cancer Research Foundation | Tetrapeptide |
US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
CA2000048A1 (en) * | 1988-10-03 | 1990-04-03 | Edward F. Plow | Peptides and antibodies that inhibit integrin-ligand bindin g |
CA2062795A1 (en) * | 1989-06-29 | 1990-12-30 | Michael W. Fanger | Bispecific reagents for aids therapy |
US5332567A (en) * | 1989-08-24 | 1994-07-26 | Immunomedics | Detection and treatment of infections with immunoconjugates |
WO1991005871A1 (en) * | 1989-10-20 | 1991-05-02 | Medarex, Inc. | Bispecific heteroantibodies with dual effector functions |
DK0496818T3 (da) * | 1989-10-20 | 1999-11-22 | Dartmouth College | IgA-receptor-specifikt monoklonalt antistof |
US5349053A (en) * | 1990-06-01 | 1994-09-20 | Protein Design Labs, Inc. | Chimeric ligand/immunoglobulin molecules and their uses |
GB2246779B (en) * | 1990-08-03 | 1994-08-17 | Delta Biotechnology Ltd | Tumour-associated protease inhibitors targeted to tumour cells |
GB9101550D0 (en) * | 1991-01-24 | 1991-03-06 | Mastico Robert A | Antigen-presenting chimaeric protein |
IL103059A0 (en) * | 1991-09-30 | 1993-02-21 | Boehringer Ingelheim Int | Conjugates for introducing nucleic acid into higher eucaryotic cells |
NZ244306A (en) * | 1991-09-30 | 1995-07-26 | Boehringer Ingelheim Int | Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation |
US5521291A (en) * | 1991-09-30 | 1996-05-28 | Boehringer Ingelheim International, Gmbh | Conjugates for introducing nucleic acid into higher eucaryotic cells |
GB9223084D0 (en) * | 1992-11-04 | 1992-12-16 | Imp Cancer Res Tech | Compounds to target cells |
GB9300686D0 (en) * | 1993-01-15 | 1993-03-03 | Imp Cancer Res Tech | Compounds for targeting |
WO1994017832A1 (en) * | 1993-02-09 | 1994-08-18 | The Scripps Research Institute | Targeting and delivery of genes and antiviral agents into cells by the adenovirus penton |
DE4311651A1 (de) * | 1993-04-08 | 1994-10-13 | Boehringer Ingelheim Int | Virus für den Transport von Fremd-DNA in höhere eukaryotische Zellen |
US5543328A (en) * | 1993-08-13 | 1996-08-06 | Genetic Therapy, Inc. | Adenoviruses having modified fiber proteins |
IT1271461B (it) * | 1993-12-01 | 1997-05-28 | Menarini Ricerche Sud Spa | Anticorpo monoclonale bispecifico anti-cd3/anti-egfr,processo per la produzione e suo uso. |
US5443953A (en) * | 1993-12-08 | 1995-08-22 | Immunomedics, Inc. | Preparation and use of immunoconjugates |
US5928944A (en) * | 1994-02-04 | 1999-07-27 | The United States Of America As Represented By The Department Of Health And Human Services | Method of adenoviral-medicated cell transfection |
US6312699B1 (en) * | 1994-03-28 | 2001-11-06 | Uab Research Foundation | Ligands added to adenovirus fiber |
JPH09509329A (ja) * | 1994-05-13 | 1997-09-22 | チロン ビアジーン,インコーポレイティド | 遺伝子搬送媒体を標的とする組成物及び方法 |
US5559099A (en) * | 1994-09-08 | 1996-09-24 | Genvec, Inc. | Penton base protein and methods of using same |
-
1994
- 1994-09-08 US US08/303,162 patent/US5559099A/en not_active Expired - Lifetime
-
1995
- 1995-08-07 JP JP8509488A patent/JPH10505242A/ja not_active Ceased
- 1995-08-07 WO PCT/US1995/009904 patent/WO1996007734A2/en active IP Right Grant
- 1995-08-07 EP EP95928312A patent/EP0778889B1/de not_active Expired - Lifetime
- 1995-08-07 CA CA002198861A patent/CA2198861A1/en not_active Abandoned
- 1995-08-07 EP EP06003302A patent/EP1679376A3/de not_active Withdrawn
- 1995-08-07 DE DE69535103T patent/DE69535103D1/de not_active Expired - Lifetime
- 1995-08-07 AT AT95928312T patent/ATE332363T1/de not_active IP Right Cessation
- 1995-08-07 AU AU32129/95A patent/AU684220B2/en not_active Ceased
-
1996
- 1996-04-17 US US08/634,060 patent/US5712136A/en not_active Expired - Lifetime
- 1996-09-06 US US08/709,515 patent/US5731190A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
US5731190A (en) | 1998-03-24 |
EP1679376A2 (de) | 2006-07-12 |
AU684220B2 (en) | 1997-12-04 |
US5559099A (en) | 1996-09-24 |
WO1996007734A3 (en) | 1996-05-09 |
EP1679376A3 (de) | 2006-08-16 |
CA2198861A1 (en) | 1996-03-14 |
EP0778889B1 (de) | 2006-07-05 |
AU3212995A (en) | 1996-03-27 |
DE69535103D1 (de) | 2006-08-17 |
EP0778889A2 (de) | 1997-06-18 |
WO1996007734A2 (en) | 1996-03-14 |
US5712136A (en) | 1998-01-27 |
JPH10505242A (ja) | 1998-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE332363T1 (de) | Rekombinanter adenovirus welcher eine chimäre penton-base aufweist | |
CA2213343A1 (en) | Chimeric adenoviral fiber protein and methods of using same | |
PT797676E (pt) | Vector adenoviral recombinante e metodos de utilizacao | |
PT737207E (pt) | Inibidores de plasmina humana derivados de dominios kunitz | |
FI943389A0 (fi) | Bacillus-lajista saatu ksylanaasi, tällaisen ksylanaasin ja muiden proteiinien ekspressiovektori, niiden isäntäorganismit ja käyttö | |
DE68927025D1 (de) | HIV-2-Virusvarianten | |
NO960309L (no) | Agonister og antagonister for humaninterleukin-10 | |
DE69518760D1 (de) | Wachstumsdifferenzierungsfaktor-12 | |
BR9607583B1 (pt) | plasmìdios procarióticos recombinantes. | |
ATE529434T1 (de) | Transfektionskomplexe | |
NO910982L (no) | Uratoksydase-aktivt protein, rekombinant gen som koder for det, ekspresjonsvektor, mikroorganismer og transformerteceller. | |
DK1025236T3 (da) | Human checkpoint kinase, HCDS1, præparater og fremgangsmåde | |
AU7077898A (en) | Recombinant vectors derived from adeno-associated virus suitable for gene therapy | |
DE3688324D1 (de) | Dna-sequenzen, die fuer proteine mit der biologischen aktivitaet der husi-typi-inhibitoren codieren, gentechnologische verfahren zur herstellung dieser proteine und diese proteine enthaltende arzneimittel. | |
HUP9902150A3 (en) | Recombinant adenoviral vectors for human tumour gene therapy | |
FI971275A (fi) | Inaktivoidun IVa2-geenin käsittävät epätäydelliset yhdistelmä-DNA-tekniset adenovirukset | |
FI971377A0 (fi) | Adenovirusperäisiä virusvektoreita, joissa on kaksi terapeuttista geeniä: itsemurha- ja immuunistimuloiva geeni | |
EP0490383A3 (en) | Peptides of the hiv-gag protein, their preparation and use | |
ATE45980T1 (de) | Molekulare klonierung und charakterisierung der fuer das schweine-relaxin kodierenden gen-sequenz. | |
FI960951A (fi) | Akarboosibiosynteesigeenejä Actinoplanes sp:stä, menetelmiä niiden eristämiseksi sekä niiden käyttö | |
ZA916106B (en) | Cloning and expression of a rhoptry-associated protein of p.falciparum | |
IL104086A0 (en) | Novel translational activating sequence | |
MX9704102A (es) | Transferencia de genes en las motoneuronas medulares por medio de vectores adenovirales. | |
SI0889969T1 (sl) | Rekombinantni adenovirusni vektorji za gensko terapijo humanih tumorjev | |
ATE102252T1 (de) | Rekombinantes gefluegelpockenvirus, expressionsvektoren fuer heterologische proteine und davon derivierte gefluegelvakzine. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |